Skip to main content

Table 1 Clinical characteristics of all patients and in survivors or non-survivors

From: Distribution and prognostic value of left ventricular global longitudinal strain in elderly patients with symptomatic severe aortic stenosis undergoing transcatheter aortic valve replacement

 

All

(n = 411)

Survivor

(n = 333)

Non-survivor

(n = 78)

P value

Survivor versus non-survivor

Age (years)

80.1 ± 7.1

79.9 ± 7.2

81.0 ± 6.2

0.24

Female sex

46.0% (189/411)

46.3 (154/333)

44.9 (35/78)

0.83

BMI (kg/m2)

26.5 ± 4.5

26.7 ± 4.6

25.7 ± 4.0

0.09

Body surface area (m2)

1.80 ± 0.20

1.85 ± 0.20

1.84 ± 0.21

0.63

Systolic blood pressure (mmHg)

141 ± 23

142 ± 22

142 ± 29

0.91

Diastolic blood pressure (mmHg)

75 ± 12

74 ± 12

76 ± 13

0.64

Creatinine clearance (ml/min)

60 (IQR 28)

62 (QR 28)

57 (IQR 27)

0.25

Eurolog II (%)

3.1 (IQR 3.4)

2.9 (IQR 2.8)

4.3 (IQR 5.7)

0.0001

Hemodialysis

1.0% (4/411)

0.9% (3/333)

1.3% (1/78)

0.76

Previous myocardial infarction

12.0% (46/385)

10.4% (32/309)

18.4% (14/76)

0.05

Hypertension

72.5% (271/374)

73.8% (222/301)

67.1% (49/73)

0.26

COPD

15.8% (65/411)

15.0% (50/333)

19.2% (15/78)

0.36

PAD

14.4% (59/410)

13.3% (44/332)

19.2% (15/78)

0.18

DM2

18.3% (68/372)

18.3% (55/301)

18.3% (13/71)

0.99

NYHA I–II

22.5% (92/409)

24.5% (81/331)

14.1% (11/78)

0.0001

NYHA III

68.7% (281/409)

69.5% (230/331)

65.4% (51/78)

NYHA IV

8.8% (36/409)

6.0% (20/331)

20.5% (16/78)

Medications

Statins

59.0% (222/379)

59.7% (181/303)

56.2% (41/73)

0.58

Beta blockers

50.1% (204/407)

48.6% (161/331)

56.6% (43/76)

0.21

Calcium antagonists

25.0% (102/408)

26.2% (87/332)

19.7% (15/76)

0.24

ACE inhibitors/ARB

33.3% (136/408)

34.0% (113/332)

30.3% (23/76)

0.53

Anticoagulant treatment

26.2% (107/408)

24.4% (81/332)

34.2% (27/76)

0.08

Thrombocyte inhibitors

40.7% (166/408)

42.8% (142/332)

31.6% (24/76)

0.07

Valve characteristics

Valve type

Edwards S3

80.3% (330/411)

79.9% (266/333)

82.1% (64/78)

0.73

Edwards XT

9.7% (40/411)

9.3% (31/333)

11.5% (9/78)

Evolute

1.9% (8/411)

2.4% (8/333)

0% (0/78)

Lotus

1.7% (7/411)

1.8% (6/333)

1.3% (1/78)

Others

6.4% (26/411)

6.6% (22/333)

5.1% (4/78)

Valve size (mm)

26.1 ± 2.4

26.0 ± 2.4

26.5 ± 2.3

0.10

  1. BMI, Body Mass Index; COPD, Chronic Obstructive Pulmonary Disease; PAD, Peripheral Artery Disease; DM2, Type 2 Diabetes Mellitus; NYHA, New York Heart Association Class; ACE, Angiotensin Converting Enzyme; ARB, Angiotensin Receptor Blocker
  2. Presented as mean ± SD, median (interquartile range) or fraction (%)